Orticumab

Names

[ Name ]:
Orticumab

Biological Activity

[Description]:

Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[In Vitro]

Orticumab (10 μg/mL；24 小时) 增加 oxLDL 刺激后体外培养的 PBMC 中的 CD14+ ICOS-L+ 群体[1]。

[In Vivo]

Orticumab (10 毫克/小鼠；腹腔注射；每周一次，持续 3 周) 减少主动脉弓中的动脉粥样硬化，减少 CD68 巨噬细胞瓣膜下斑块染色[1]。 Animal Model: B6.lpr.ApoE-/- mice (18-week-old) fed with high-fat diet (HFD)[1] Dosage: 10 mg/mouse Administration: Intraperitoneal injection; once weekly for 3 weeks Result: Reduced atherosclerosis in the aortic arch by 42.8%, decreased the CD68-macrophage subvalvular plaque staining by 30.5%.

[References]

[1]. Yao Mattisson I, et al. Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus. Vascul Pharmacol. 2021 Oct;140:106863.

[2]. Liang BC, et al. Compositions and methods with anti-ApoB100 antibody or fragment for treatment of psoriasis: World Intellectual Property Organization, WO2019232070 A1. 2019-12-05.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.